- Lineage Cell Therapeutics ( NYSE: LCTX ) said on Monday the United States Patent and Trademark Office had issued a patent for the company's application with claims covering manufacturing processes for its oligodendrocyte progenitor cell therapy candidate (OPC1) for the treatment of spinal cord injury.
- The patent, which is expected to be issued in the coming months, would have a term that would expire no earlier than 2040.
- Lineage aims to provide cell-based therapy to patients by replacing cells lost due to disease, aging, or in the case of spinal cord injury.
- The Company currently is focused on preparing for a planned interaction with the U.S. Food and Drug Administration this quarter to discuss its OPC1 Investigational New Drug ( IND ) amendment submission.
For further details see:
Lineage receives U.S. patent for spinal cord injury treatment